Další formáty:
BibTeX
LaTeX
RIS
@article{1217807, author = {Kubatka, Peter and Kružliak, Peter and Rotrekl, Vladimír and Jelínková, Šárka and Mladosievicova, Beata}, article_location = {New York}, article_number = {3}, doi = {http://dx.doi.org/10.1016/j.critrevonc.2014.08.002}, keywords = {Anti-tumor properties; Cancer risk reduction; Cancer therapy; Carcinogenesis; Chemoprevention; Statins}, language = {eng}, issn = {1040-8428}, journal = {Critical Reviews in Oncology/Hematology}, title = {Statins in oncological research: From experimental studies to clinical practice}, volume = {92}, year = {2014} }
TY - JOUR ID - 1217807 AU - Kubatka, Peter - Kružliak, Peter - Rotrekl, Vladimír - Jelínková, Šárka - Mladosievicova, Beata PY - 2014 TI - Statins in oncological research: From experimental studies to clinical practice JF - Critical Reviews in Oncology/Hematology VL - 92 IS - 3 SP - 296-311 EP - 296-311 PB - Elsevier Science Inc. SN - 10408428 KW - Anti-tumor properties KW - Cancer risk reduction KW - Cancer therapy KW - Carcinogenesis KW - Chemoprevention KW - Statins N2 - Statins, 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors are commonly used drugs in the treatment of dyslipidemias, primarily raised cholesterol. Recently, many epidemiological and preclinical studies pointed to anti-tumor properties of statins, including anti-proliferative activities, apoptosis, decreased angiogenesis and metastasis. These processes play an important role in carcinogenesis and, therefore, the role of statins in cancer disease is being seriously discussed among oncologists. Anti-neoplastic properties of statins combined with an acceptable toxicity profile in the majority of individuals support their further development as anti-tumor drugs.The mechanism of action, current preclinical studies and clinical efficacy of statins are reviewed in this paper. Moreover, promising results have been reported regarding the statins' efficacy in some cancer types, especially in esophageal and colorectal cancers, and hepatocellular carcinoma. Statins' hepatotoxicity has traditionally represented an obstacle to the prescription of this class of drugs and this issue is also discussed in this review. ER -
KUBATKA, Peter, Peter KRUŽLIAK, Vladimír ROTREKL, Šárka JELÍNKOVÁ a Beata MLADOSIEVICOVA. Statins in oncological research: From experimental studies to clinical practice. \textit{Critical Reviews in Oncology/Hematology}. New York: Elsevier Science Inc., 2014, roč.~92, č.~3, s.~296-311. ISSN~1040-8428. Dostupné z: https://dx.doi.org/10.1016/j.critrevonc.2014.08.002.
|